Progressive multifocal leukoencephalopathy: rheumatological aspects
https://doi.org/10.14412/1996-7012-2015-3-4-9
Abstract
Progressive multifocal leukoencephalopathy (PML) is a severe progressive viral disease that affects the central nervous system in patients with immunodeficiency. It may develop as a complication in patients with systemic inflammatory rheumatic diseases (primarily in those with systemic lupus erythematosus), including that during active antirheumatic therapy. The paper presents data on the etiology, epidemiology, and pathogenesis of the disease, characterizes its clinical presentation, highlights main approaches to its diagnosis, and gives current diagnostic criteria. A questionnaire used to monitor neurological status is shown. The paper emphasizes the importance of this monitoring, for early diagnosis and timely cessation of PML treatment with a drug, a potential trigger, are factors that influence prognosis to the utmost degree.
About the Author
Boris Sergeevich Belov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leukoencephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain. 1958 Mar;81(1):93–111.
2. Calabrese LH, Molloy E, Berger J. Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol. 2015;11(2):119–23. doi:10.1038/nrrheum.2014.167.
3. Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1(7712):1257–60.
4. Bag AK, Curе JK, Chapman PR, et al. JC-virus infection of the brain. Am J Neuroradiol. 2010;31(9):1564–76. doi: 10.3174/ajnr.A2035.
5. Tan SK, Koralnik I. JC, BK and other polyomaviruses: Progressive multifocal leucoencephalopathy. In: Bennet JE, Dolin R, Blaser MJ, editors.Mandel, Douglas and Bennet’s principles and practice of infectious diseases, 8th ed. New York: Saunders; 2015. P. 1574–89.
6. Berger JR, Aksamit AJ, Clifford DB et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430–8. doi: 10.1212/WNL.0b013e31828c2fa1
7. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56(7):2116–28. DOI: 10.1002/art.22657.
8. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761–5. doi: 10.1002/art.24966.
9. Arkema EV, van Vollenhoven RF, Askling J; ARTIS Study Group. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis. 2012;71(11):1865–7. doi: 10.1136/annrheumdis-2012-201638.
10. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–80. doi: 10.1056/NEJMoa1107829.
11. Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65(3): 546–51. doi: 10.1016/j.jaad.2010.05.033.
12. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043–51. doi: 10.1002/art.34468.
13. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with biologic therapy in rheumatic diseases: strengthening association with rituximab. Arthritis Rheum. 2014;66(Suppl 10):369.
14. Belhassen-Garcia M, Rabano-Gutierrez A, Velasco-Tirado V, et al. Atypical progressive multifocal leukoencephalopathy in a patient with antisynthetase syndrome. Intern Med. 2015;54(5):519–24. doi: 10.2169/internalmedicine.54.2748
15. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab the University of North Carolina at Chapel Hill. Arthritis Rheum 2010; 62(11):3191–5. doi: 10.1002/art.27687
16. Yamamoto M, Takahashi H, Wakasugi H, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol. 2007;17(1):72–4. doi:10.1007/s10165-006-0530-2.
17. Ray M, Curtis JR, Baddley JW. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis. 2014;73(7):1429–30. doi: 10.1136/annrheumdis-2013-204978
18. Kobayashi K, Okamoto Y, Inoue H, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis. Intern Med. 2009;48(15):1307–9. Epub 2009 Aug 3. http://dx.doi.org/10.2169/internalmedicine.48.1926.
19. Lach B, Connolly B, Wü thrich C, Koralnik IJ. Inflammatory infratentorial progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis. Neuropathology. 2014;34(1):39–44. doi: 10.1111/neup.12045.
20. Rahmlow M, Shuster EA, Dominik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol. 2008;65(11):1538–9. doi: 10.1001/archneur.65.11.1538.
21. Molloy ES. PML and rheumatology: the contribution of disease and drugs. Cleve Clin J Med. 2011 Nov;78 Suppl 2:S28–32. doi: 10.3949/ccjm.78.s2.07.
22. Письмо Федеральной службы по надзору в сфере здравоохранения от 7 февраля 2014 г. № 02И-110/14 «О новых данных по безопасности лекарственного препарата Бенлиста». [The letter of the Federal service for supervision in the sphere of health № 02И-110/14 dated February, 07 2014 «About new data about safety of drug Benlysta». (in Russ.)]. http://www.garant.ru/products/ipo/prime/doc/70485650/#ixzz3OWJlGxDT .
23. Vinhas de Souza M, Keller-Stanislawski B, Blake K, et al. Drug-induced PML: a global agenda for a global challenge. Clin Pharmacol Ther. 2012;91(4):747–50. doi: 10.1038/clpt.2012.4.
24. Steiner I, Berger JR. Update on progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep. 2012;12(6):680–6. doi: 10.1007/s11910-012-0313-4.
25. Verheyen J, Maizus K, Feist E, et al. Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics. Med Microbiol Immunol. 2015;204(5):613–8. doi: 10.1007/s00430-015-0390-5/
26. US Food and Drug Administration. Center for drug evaluation and research.Briefing document for the joint meeting of the Gastrointestinal Drugs Advisory Committee (CIDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRMAC). December, 9, 2013. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Gastroi
27. ntestinalDrugs/AdvisoryCommittee/UCM377618.pdf.
28. Borie D, Kremer JM. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2015 Jun 17. pii: S0049–0172(15)00141–9. doi: 10.1016/j.semarthrit.2015.06.003
Review
For citations:
Belov BS. Progressive multifocal leukoencephalopathy: rheumatological aspects. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2015;9(3):4-9. (In Russ.) https://doi.org/10.14412/1996-7012-2015-3-4-9
Views:
2110
Email this article 